Login to Your Account

Acquisition Likely: Not 'If' but 'When'

ThromboGenics Banks $59M Milestone on EU Approval

By Cormac Sheridan
Staff Writer

Wednesday, March 20, 2013
ThromboGenics NV is banking a €45 million (US$58.8 million) milestone payment from its partner, Alcon, a unit of Novartis AG, following formal European Union (EU) approval for Jetrea (ocriplasmin) for treating patients with vitreomacular traction (VMT), including those with a macular hole up to 400 microns in diameter.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription